D-0102-2024 Class I Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0102-2024 was initiated by Pfizer Inc. on Oct 2, 2023 and is designated Class I. Reason for recall: Presence of Particulate Matter: identified as glass. The recall status is terminated (terminated Feb 14, 2025). Affected quantity: 3,200 vials.

Recall details

Product Type
Drugs
Report Date
Nov 15, 2023
Initiation Date
Oct 2, 2023
Termination Date
Feb 14, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,200 vials

Product description

2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Distributed by Hospira Inc., Lake Forest, IL 60045, NDC 0409-4903-11

Reason for recall

Presence of Particulate Matter: identified as glass.

Distribution pattern

Nationwide in the US and Puerto Rico. The products were not distributed to government accounts or foreign consignees.

Code information

Lot#: GH6567, Exp. 7/1/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0102-2024
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0102-2024. Report a data issue: hello@regdatalab.com.